Evidence map›Paper›PMID 40700605›Full record

ArticleJNCI cancer spectrum2025

Impact of postoperative fluorodeoxyglucose positron emission tomography/computed tomography on adjuvant head and neck cancer treatment.

P Travis Courtney, Jesus E Juarez Casillas, Eulanca Y Liu, Myung-Shin Sim, Lydia W Chau, Rafael E Lopez-Chicas, Maie A St John, Elliot Abemayor, Keith E Blackwell, Dinesh K Chhetri and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JNCI cancer spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

P Travis CourtneyDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, United States.ORCID 0000-0001-7625-3678
Jesus E Juarez CasillasDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, United States.ORCID 0000-0002-9604-992X
Eulanca Y LiuDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, United States.ORCID 0000-0002-8600-7160
Myung-Shin SimDepartment of Medicine Statistics Core, Division of General Internal Medicine and Health Services Research, University of California, Los Angeles, Los Angeles, CA, United States.ORCID 0000-0001-9706-1499
Lydia W ChauDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, United States.
Rafael E Lopez-ChicasDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, United States.
Maie A St JohnHead and Neck Cancer Program, University of California, Los Angeles, Los Angeles, CA, United States.
Elliot AbemayorHead and Neck Cancer Program, University of California, Los Angeles, Los Angeles, CA, United States.
Keith E BlackwellHead and Neck Cancer Program, University of California, Los Angeles, Los Angeles, CA, United States.
Dinesh K ChhetriHead and Neck Cancer Program, University of California, Los Angeles, Los Angeles, CA, United States.
Quinton S GopenHead and Neck Cancer Program, University of California, Los Angeles, Los Angeles, CA, United States.
Paul A KedeshianHead and Neck Cancer Program, University of California, Los Angeles, Los Angeles, CA, United States.ORCID 0009-0000-1562-421X
Rhorie P KerrHead and Neck Cancer Program, University of California, Los Angeles, Los Angeles, CA, United States.
Jivianne K LeeHead and Neck Cancer Program, University of California, Los Angeles, Los Angeles, CA, United States.
Vishad NabiliHead and Neck Cancer Program, University of California, Los Angeles, Los Angeles, CA, United States.
Joel A SercarzHead and Neck Cancer Program, University of California, Los Angeles, Los Angeles, CA, United States.
Jeffrey D SuhHead and Neck Cancer Program, University of California, Los Angeles, Los Angeles, CA, United States.
Marilene B WangHead and Neck Cancer Program, University of California, Los Angeles, Los Angeles, CA, United States.ORCID 0000-0002-2799-6325
Deborah J WongHead and Neck Cancer Program, University of California, Los Angeles, Los Angeles, CA, United States.ORCID 0000-0002-7811-7247
Wanxing Chai-HoHead and Neck Cancer Program, University of California, Los Angeles, Los Angeles, CA, United States.
Mahbod G JafarvandDepartment of Nuclear Medicine, University of California, Los Angeles, Los Angeles, CA, United States.ORCID 0000-0002-8555-4787
Shadfar BahriDepartment of Nuclear Medicine, University of California, Los Angeles, Los Angeles, CA, United States.ORCID 0000-0002-2622-389X
Erika JankDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, United States.ORCID 0009-0003-7216-9016
Vishruth K ReddyDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, United States.ORCID 0000-0002-9150-7784
Michael L SteinbergDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, United States.
Robert K ChinDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, United States.ORCID 0000-0002-3421-6403
Ricky R SavjaniDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, United States.

Funding

NRSA Training CoreTL1TR001883 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ALEX BUI, Nina Thawata Harawa · 2016 to 2026
$8.6M
National Institutes of Health/National Center for Advancing Translational ScienceNCATS NIH HHS TL1 TR001883
6 · The paper itself

Abstract

backgroundResidual or recurrent cancer after surgery but prior to adjuvant therapy occurs in a proportion of patients with head and neck cancer and may warrant treatment changes. 18-Fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) may help to identify residual or recurrent disease but is not routinely obtained. We evaluated the relevance of postoperative FDG-PET/CT in this clinical context.

methodsThis single-institution, retrospective study identified patients with head and neck cancer who underwent definitive surgery between January 1, 2013, and April 1, 2023, and received a postoperative FDG-PET/CT prior to adjuvant treatment. We measured the rates of management changes resulting from postoperative FDG-PET/CT findings and the association between having a postoperative FDG-PET/CT which resulted in a management change and oncologic outcomes with selected multivariable competing-risks and proportional hazards regressions.

resultsOf 150 patients, 66 (44.0%) had a management change because of the postoperative FDG-PET/CT findings; 62 (93.8%) had radiotherapy plan changes, 20 (30.3%) underwent additional diagnostic testing, 11 (16.7%) had systemic therapy added or changed, 3 (4.6%) underwent reresection, and 15 (10.0%) switched to palliative-intent treatment. Having a postoperative FDG-PET/CT that resulted in a management change was not significantly associated with cancer recurrence or overall survival (both P > .05).

conclusionsIn patients with resected head and neck cancer, postoperative, pre-adjuvant therapy FDG-PET/CT can alter clinical management and may enable additional personalization of treatment. When practical to obtain without delaying treatment, postoperative FDG-PET/CT may have clinical utility though requires careful interpretation due to the risks of false positives.

Indexed as

Fluorodeoxyglucose F18Head and Neck NeoplasmsNeoplasm Recurrence, LocalPositron Emission Tomography Computed TomographyAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm, ResidualPostoperative PeriodRadiopharmaceuticalsRetrospective StudiesFluorodeoxyglucose F18Radiopharmaceuticals

Identifiers

PMID40700605
PMCPMC12349773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.